JAMA Medical News What's Next in Weight-Loss Drugs?
12 snips
Jan 30, 2026 Rita Rubin, Lead Senior Staff Writer for JAMA Medical News who covers clinical and public health reporting, walks through three upcoming weight-loss drugs. Short takes on injectable semaglutide doses versus an oral option. Trial results and combo therapy outcomes are discussed. Practical factors for choosing treatments like dosing, side effects, and insurance are highlighted.
AI Snips
Chapters
Transcript
Episode notes
Three New Weight-Loss Options
- Three new obesity drugs likely to be approved include high-dose semaglutide, semaglutide+cagrillentide, and oral orforglopron.
- Orforglopron would be the second daily GLP-1 pill and avoids timing restrictions required by oral semaglutide.
Large Weight Loss Seen In Phase 3 Trials
- Phase 3 trials showed substantial mean weight loss: up to ~21% with very high-dose semaglutide and ~20% with semaglutide+cagrillentide.
- Placebo groups lost only about 2–3%, and effects in people with diabetes were similar but smaller.
Pick Based On Preference And Coverage
- Choose between injectables and pills based on personal preference for injections versus daily dosing and convenience.
- Ultimately, insurance coverage and out-of-pocket cost will largely determine which drug patients can access.